The increasing occurrence of genetic disorders is a major factor fueling the demand for oligonucleotide synthesis, as these molecules are essential for gene therapies and diagnostics aimed at ...

It is important to stress that the oligonucleotide probes are designed using the same set of composition rules regardless of the organism or set of RNAs interrogated. This consistency of design ...

Rockland Immunochemicals, Inc. is pleased to announce that Dr. David P. Chimento, Vice President of Research and Development, Amy L. Anderson, Technical Applications Specialist, and Dr. Carl Ascoli, ...

The article, titled "Bioanalytical Assays for Oligonucleotide Therapeutics: Adding Antibody-based Immunoassays to the Toolbox as an Orthogonal Approach to LC-MS/MS and Ligand Binding Assays ...

Pepgen Inc. seems to have gained a leg up on competitors in early data with PGN-EDODM1 in myotonic dystrophy type 1 (DM1), ...

Oligonucleotide therapeutics are becoming increasingly popular, with scientists developing treatments for rare diseases, cancer, and respiratory disorders. To ensure their quality, researchers must ...

Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...

Delray Beach, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, reaching US$2.51 billion ...

With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...